Clinical trials: Arthritis, Rheumatoid (RA)
Rheumatoid Arthritis
An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis
This observational study evaluates the use and efficacy of intravenous (IV) tocilizumab in routine clinical practice in participants with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01741688
- Testing
- Tocilizumab
- Where
- 4 sites in Peru
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
This 2 arm study will compare the incidence of tocilizumab-related infusion reactions, using 2 different infusion times, in patients with moderate to severe rheumatoid arthritis who have shown an inadequate response to DMARDs…
- Trial name
- NCT00887341
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 24 sites in Spain
- Volunteers
- 76 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- REASSURE (NCT01377012)
- Testing
- Secukinumab (AIN457)
- Where
- 142 sites in United States, Argentina and 14 more
- Volunteers
- 637 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis (RA), Arthritis, Rheumatoid (RA)
Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life)
The goal of this clinical trial is to learn if the PREVAIL model of care is a feasible way to integrate rehabilitation into routine rheumatology care for adults with rheumatoid arthritis (RA).
- Trial name
- NCT06706999
- Testing
- PREVAIL model of care
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of North Carolina, Chapel Hill
Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid…
- Trial name
- PREDICTRA (NCT02198651)
- Testing
- Adalimumab
- Where
- 70 sites in United States, Australia and 12 more
- Volunteers
- 149 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
Methotrexate-Inadequate Response Study
The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an…
- Trial name
- NCT00559585
- Testing
- Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept
- Where
- 203 sites in United States, Argentina and 22 more
- Volunteers
- 2,492 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe…
- Trial name
- NCT01500278
- Testing
- Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX)
- Where
- 175 sites in United States, Australia and 18 more
- Volunteers
- 915 people
- Sponsor
- UCB Pharma SA
Rheumatoid Arthritis
Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)
This study is multicenter, Ph IV, single arm, interventional study to assess relative reduction of morning stiffness of Lodotra® in Rheumatoid Arthritis patients.Study medication will start after study visit at baseline (week 0…
- Trial name
- NCT02072200
- Testing
- Lodotra®
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Mundipharma Korea Ltd
Rheumatoid Arthritis
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.
- Trial name
- NCT00805467
- Testing
- Fostamatinib Disodium (R935788)
- Where
- 76 sites in United States, Belgium and 9 more
- Volunteers
- 624 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis
CRx-102 is a synergistic combination drug candidate containing the cardiovascular drug dipyridamole and a very low dose of the glucocorticoid prednisolone.
- Trial name
- MARS-1 (NCT00551707)
- Testing
- CRx-102 (2.7/180), prednisolone, dipyridamole
- Where
- 48 sites in United States, Argentina and 10 more
- Volunteers
- 51 people
- Sponsor
- Zalicus
Rheumatoid Arthritis
An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients.
This observational study will describe the treatment patterns of usage of biological DMARDs in routine clinical practice and the demographics and RA disease characteristics in patients suffering from rheumatoid arthritis.
- Trial name
- NCT02590562
- Testing
- Routine clinical practice
- Where
- 15 sites in China
- Volunteers
- 808 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis (RA)
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the…
- Trial name
- NCT03086343
- Testing
- Abatacept, Upadacitinib
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 657 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.
- Trial name
- NCT05279417
- Testing
- ATI-450 50 mg oral tablet BID, Methotrexate, ATI-450 20 mg oral tablet BID
- Where
- 50 sites in United States, Bulgaria and 2 more
- Volunteers
- 251 people
- Sponsor
- Aclaris Therapeutics, Inc.
Rheumatoid Arthritis
Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy
RA (Rheuatoid arthritis) is a multisystem disease that mainly involves joints resulting in destructive arthritis if not treated rapidly.
- Trial name
- NCT02930343
- Testing
- Methotrexate, Leflunomide, Hydroxychloroquine
- Where
- India
- Volunteers
- 136 people
- Sponsor
- Jawaharlal Institute of Postgraduate Medical Education & Research
Arthritis, Rheumatoid
Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA
The primary purpose of this study is to evaluate the safety and efficacy of a once-weekly dose of etanercept for rheumatoid arthritis. Currently, patients in Japan can only use 25 mg etanercept two times a week.
- Trial name
- NCT00418717
- Testing
- etanercept
- Where
- 12 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer